{"id":14773,"date":"2025-06-28T00:00:00","date_gmt":"2025-06-27T17:00:00","guid":{"rendered":"https:\/\/www.nanovest.io/blog\/uncategorized\/pfizer-optimis-hadapi-tantangan-kebijakan-dan-proyeksi-laba-2025-14773\/"},"modified":"2025-06-28T00:00:00","modified_gmt":"2025-06-27T17:00:00","slug":"pfizer-optimis-hadapi-tantangan-kebijakan-dan-proyeksi-laba-2025","status":"publish","type":"post","link":"https:\/\/www.nanovest.io/blog\/berita\/pfizer-optimis-hadapi-tantangan-kebijakan-dan-proyeksi-laba-2025-14773\/","title":{"rendered":"Pfizer Optimis Hadapi Tantangan Kebijakan dan Proyeksi Laba 2025"},"content":{"rendered":"<p><p><a href=\"https:\/\/www.nanovest.io\/en\/us-stocks\/pfe\/\">Pfizer (PFE.N)<\/a>\u00a0pada hari Selasa menyatakan bahwa mereka tidak mengharapkan pemerintahan Trump untuk membuat perubahan besar pada kebijakan vaksin tahun depan, meskipun presiden terpilih tersebut telah mencalonkan Robert F. Kennedy Jr., seorang skeptis vaksin, sebagai Menteri Kesehatan dan Layanan Kemanusiaan (HHS).<\/p>\n<p>CEO Pfizer, Albert Bourla, mengatakan kepada analis dalam sebuah konferensi investor bahwa ia telah bertemu dengan RFK Jr. dan Trump untuk makan malam, mengonfirmasi laporan media sebelumnya, dan mengaku telah membangun hubungan baik dengan Kennedy.<\/p>\n<p>> \u201cJika dia dikonfirmasi, kami akan bekerja sama dengannya untuk memastikan kebijakan yang tepat dapat dijalankan,\u201d kata Bourla.<\/p>\n<p>Kennedy selama ini dikenal meragukan keamanan dan efektivitas vaksin, meskipun vaksin telah membantu menekan penyakit dan menyelamatkan nyawa selama beberapa dekade. Namun, Kennedy membantah label anti-vaksinasi dan menyatakan bahwa ia tidak akan melarang orang Amerika untuk mendapatkan vaksin. Sementara itu, Trump menyebutkan bahwa ia mungkin menghentikan beberapa vaksinasi anak-anak jika ia menganggap vaksin tersebut berbahaya.<\/p>\n<p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_86 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Daftar Isi <\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.nanovest.io/blog\/berita\/pfizer-optimis-hadapi-tantangan-kebijakan-dan-proyeksi-laba-2025-14773\/#Trump_Berkomitmen_Mereformasi_Sistem_Perawatan_Kesehatan\" >Trump Berkomitmen Mereformasi Sistem Perawatan Kesehatan<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.nanovest.io/blog\/berita\/pfizer-optimis-hadapi-tantangan-kebijakan-dan-proyeksi-laba-2025-14773\/#Proyeksi_Laba_dan_Tantangan_Pfizer_di_Masa_Depan\" >Proyeksi Laba dan Tantangan Pfizer di Masa Depan<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.nanovest.io/blog\/berita\/pfizer-optimis-hadapi-tantangan-kebijakan-dan-proyeksi-laba-2025-14773\/#Kritik_dan_Upaya_Perbaikan_Strategi_Pfizer\" >Kritik dan Upaya Perbaikan Strategi Pfizer<\/a><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Trump_Berkomitmen_Mereformasi_Sistem_Perawatan_Kesehatan\"><\/span><strong>Trump Berkomitmen Mereformasi Sistem Perawatan Kesehatan<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<\/p>\n<p>Bourla juga menambahkan bahwa Trump terlihat sangat berkomitmen untuk mereformasi peran middlemen yang dikenal sebagai pharmacy benefit managers (PBM) dalam sistem perawatan kesehatan AS. \u201cPasien akan melihat pengurangan dramatis dalam biaya yang mereka alami untuk obat-obatan mereka jika itu terjadi,\u201d katanya. Pada hari Senin, Trump mengatakan dalam konferensi pers bahwa ia berencana untuk menghapus peran PBM.<\/p>\n<p>Selain vaksin COVID-19, Pfizer juga memproduksi vaksin untuk penyakit pneumokokus dan virus pernapasan syncytial (RSV). Namun, saham Pfizer dan produsen vaksin lainnya sempat tertekan ketika Trump mengumumkan Kennedy sebagai pilihannya untuk memimpin HHS.<\/p>\n<p><h2><span class=\"ez-toc-section\" id=\"Proyeksi_Laba_dan_Tantangan_Pfizer_di_Masa_Depan\"><\/span><strong>Proyeksi Laba dan Tantangan Pfizer di Masa Depan<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<\/p>\n<p>Di hari yang sama, Pfizer memperkirakan laba tahun 2025 sejalan dengan estimasi, memberikan sedikit kelegaan bagi para investor setelah perusahaan menghadapi kritik dari pemegang saham, termasuk hedge fund Starboard, terkait strategi turnaround mereka.\u00a0<\/p>\n<p>Saham Pfizer naik 3,7% menjadi $26,20 dalam perdagangan awal setelah perusahaan juga menyatakan bahwa mereka mengharapkan penjualan vaksin dan obat COVID-19 di tahun 2025 akan sebanding dengan tingkat penjualan tahun ini.<\/p>\n<p>Setelah sukses besar produk COVID selama pandemi, Pfizer kini berada di bawah tekanan untuk menghadirkan obat baru ke pasar guna mengimbangi potensi kehilangan pendapatan dari beberapa produk andalan yang akan segera habis masa patennya. Saham perusahaan telah turun hampir 12% tahun ini dan diperdagangkan kurang dari setengah nilainya saat puncak pandemi COVID-19.<\/p>\n<p><h2><span class=\"ez-toc-section\" id=\"Kritik_dan_Upaya_Perbaikan_Strategi_Pfizer\"><\/span><strong>Kritik dan Upaya Perbaikan Strategi Pfizer<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<\/p>\n<p>Analis dalam beberapa minggu terakhir juga memangkas perkiraan laba Pfizer, yang membuat perusahaan terbuka terhadap kritik investor. Pada bulan Oktober, Starboard menuduh manajemen Pfizer menghabiskan terlalu banyak pada akuisisi besar namun gagal menghasilkan obat baru yang menguntungkan dari akuisisi tersebut maupun dari penelitian dan pengembangan internal.<\/p>\n<p>Namun, Bourla membela strategi turnaround-nya, dengan meluncurkan program penghematan biaya dan melepas bisnis non-inti untuk melunasi utang. Pfizer memperkirakan laba yang disesuaikan sebesar $2,80 hingga $3 per saham, dibandingkan dengan estimasi rata-rata analis sebesar $2,88 per saham, menurut data yang dikumpulkan oleh LSEG. Pfizer juga memproyeksikan pendapatan tahun 2025 di kisaran $61 miliar hingga $64 miliar, dibandingkan dengan estimasi sebesar $63,26 miliar.<\/p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pfizer optimis pada kebijakan vaksin di era Trump meski kritik muncul, fokus pada reformasi biaya obat, proyeksi laba 2025 stabil, dan strategi inovasi baru.<\/p>\n","protected":false},"author":28,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[80],"tags":[337],"class_list":["post-14773","post","type-post","status-publish","format-standard","category-berita","tag-saham-global"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO Pro 5.0.0.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"Pfizer optimis pada kebijakan vaksin di era Trump meski kritik muncul, fokus pada reformasi biaya obat, proyeksi laba 2025 stabil, dan strategi inovasi baru.\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"Rian Jakawardana\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/www.nanovest.io/blog\/berita\/pfizer-optimis-hadapi-tantangan-kebijakan-dan-proyeksi-laba-2025-14773\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO Pro (AIOSEO) 5.0.0.1\" \/>\n\t\t<meta property=\"og:locale\" content=\"id_ID\" \/>\n\t\t<meta property=\"og:site_name\" content=\"Blog Nanovest - Artikel dan Berita Kripto, Saham AS, dan Emas\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"Pfizer Optimis Hadapi Tantangan Kebijakan dan Proyeksi Laba 2025 - Blog Nanovest\" \/>\n\t\t<meta property=\"og:description\" content=\"Pfizer optimis pada kebijakan vaksin di era Trump meski kritik muncul, fokus pada reformasi biaya obat, proyeksi laba 2025 stabil, dan strategi inovasi baru.\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/www.nanovest.io/blog\/berita\/pfizer-optimis-hadapi-tantangan-kebijakan-dan-proyeksi-laba-2025-14773\/\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2025-06-27T17:00:00+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2025-06-27T17:00:00+00:00\" \/>\n\t\t<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/nanovest\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:site\" content=\"@nanovest_io\" \/>\n\t\t<meta name=\"twitter:title\" content=\"Pfizer Optimis Hadapi Tantangan Kebijakan dan Proyeksi Laba 2025 - Blog Nanovest\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Pfizer optimis pada kebijakan vaksin di era Trump meski kritik muncul, fokus pada reformasi biaya obat, proyeksi laba 2025 stabil, dan strategi inovasi baru.\" \/>\n\t\t<meta name=\"twitter:creator\" content=\"@nanovest_io\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/berita\\\/pfizer-optimis-hadapi-tantangan-kebijakan-dan-proyeksi-laba-2025-14773\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.nanovest.io/blog#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.nanovest.io/blog\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/category\\\/berita\\\/#listItem\",\"name\":\"Berita\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/category\\\/berita\\\/#listItem\",\"position\":2,\"name\":\"Berita\",\"item\":\"https:\\\/\\\/www.nanovest.io/blog\\\/category\\\/berita\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/berita\\\/pfizer-optimis-hadapi-tantangan-kebijakan-dan-proyeksi-laba-2025-14773\\\/#listItem\",\"name\":\"Pfizer Optimis Hadapi Tantangan Kebijakan dan Proyeksi Laba 2025\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.nanovest.io/blog#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/berita\\\/pfizer-optimis-hadapi-tantangan-kebijakan-dan-proyeksi-laba-2025-14773\\\/#listItem\",\"position\":3,\"name\":\"Pfizer Optimis Hadapi Tantangan Kebijakan dan Proyeksi Laba 2025\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/category\\\/berita\\\/#listItem\",\"name\":\"Berita\"}}]},{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/berita\\\/pfizer-optimis-hadapi-tantangan-kebijakan-dan-proyeksi-laba-2025-14773\\\/#newsarticle\",\"name\":\"Pfizer Optimis Hadapi Tantangan Kebijakan dan Proyeksi Laba 2025 - Blog Nanovest\",\"headline\":\"Pfizer Optimis Hadapi Tantangan Kebijakan dan Proyeksi Laba 2025\",\"author\":{\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/author\\\/rian-jakawardana\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/www.nanovest.io/blog\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/site-logo-color.png\",\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/#articleImage\",\"width\":250,\"height\":250,\"caption\":\"site-logo-color\"},\"datePublished\":\"2025-06-28T00:00:00+07:00\",\"dateModified\":\"2025-06-28T00:00:00+07:00\",\"inLanguage\":\"id-ID\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/berita\\\/pfizer-optimis-hadapi-tantangan-kebijakan-dan-proyeksi-laba-2025-14773\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/berita\\\/pfizer-optimis-hadapi-tantangan-kebijakan-dan-proyeksi-laba-2025-14773\\\/#webpage\"},\"articleSection\":\"Berita, Saham Global\",\"dateline\":\"Published on Juni 28, 2025.\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/#organization\",\"name\":\"Nanovest\",\"description\":\"Artikel dan Berita Kripto, Saham AS, dan Emas\",\"url\":\"https:\\\/\\\/www.nanovest.io/blog\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/www.nanovest.io/blog\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/site-logo-color.png\",\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/berita\\\/pfizer-optimis-hadapi-tantangan-kebijakan-dan-proyeksi-laba-2025-14773\\\/#organizationLogo\",\"width\":250,\"height\":250,\"caption\":\"site-logo-color\"},\"image\":{\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/berita\\\/pfizer-optimis-hadapi-tantangan-kebijakan-dan-proyeksi-laba-2025-14773\\\/#organizationLogo\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/nanovest\",\"https:\\\/\\\/twitter.com\\\/nanovest_io\",\"https:\\\/\\\/www.instagram.com\\\/nanovest.io\\\/\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UC5Y5fD2FApTWMc0c2mlxzIg\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nano-vest\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/author\\\/rian-jakawardana\\\/#author\",\"url\":\"https:\\\/\\\/www.nanovest.io/blog\\\/author\\\/rian-jakawardana\\\/\",\"name\":\"Rian Jakawardana\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/berita\\\/pfizer-optimis-hadapi-tantangan-kebijakan-dan-proyeksi-laba-2025-14773\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/629254e93aea20fec7b66121b57ce2b89b77c11bcde0df80552d7ea9f9c9defb?s=96&d=monsterid&r=g\",\"width\":96,\"height\":96,\"caption\":\"Rian Jakawardana\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/berita\\\/pfizer-optimis-hadapi-tantangan-kebijakan-dan-proyeksi-laba-2025-14773\\\/#webpage\",\"url\":\"https:\\\/\\\/www.nanovest.io/blog\\\/berita\\\/pfizer-optimis-hadapi-tantangan-kebijakan-dan-proyeksi-laba-2025-14773\\\/\",\"name\":\"Pfizer Optimis Hadapi Tantangan Kebijakan dan Proyeksi Laba 2025 - Blog Nanovest\",\"description\":\"Pfizer optimis pada kebijakan vaksin di era Trump meski kritik muncul, fokus pada reformasi biaya obat, proyeksi laba 2025 stabil, dan strategi inovasi baru.\",\"inLanguage\":\"id-ID\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/berita\\\/pfizer-optimis-hadapi-tantangan-kebijakan-dan-proyeksi-laba-2025-14773\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/author\\\/rian-jakawardana\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/author\\\/rian-jakawardana\\\/#author\"},\"datePublished\":\"2025-06-28T00:00:00+07:00\",\"dateModified\":\"2025-06-28T00:00:00+07:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/#website\",\"url\":\"https:\\\/\\\/www.nanovest.io/blog\\\/\",\"name\":\"Nanovest\",\"alternateName\":\"Blog Nanovest\",\"description\":\"Artikel dan Berita Kripto, Saham AS, dan Emas\",\"inLanguage\":\"id-ID\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO Pro -->\r\n\t\t<title>Pfizer Optimis Hadapi Tantangan Kebijakan dan Proyeksi Laba 2025 - Blog Nanovest<\/title>\n\n","aioseo_head_json":{"title":"Pfizer Optimis Hadapi Tantangan Kebijakan dan Proyeksi Laba 2025 - Blog Nanovest","description":"Pfizer optimis pada kebijakan vaksin di era Trump meski kritik muncul, fokus pada reformasi biaya obat, proyeksi laba 2025 stabil, dan strategi inovasi baru.","canonical_url":"https:\/\/www.nanovest.io/blog\/berita\/pfizer-optimis-hadapi-tantangan-kebijakan-dan-proyeksi-laba-2025-14773\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BreadcrumbList","@id":"https:\/\/www.nanovest.io/blog\/berita\/pfizer-optimis-hadapi-tantangan-kebijakan-dan-proyeksi-laba-2025-14773\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/www.nanovest.io/blog#listItem","position":1,"name":"Home","item":"https:\/\/www.nanovest.io/blog","nextItem":{"@type":"ListItem","@id":"https:\/\/www.nanovest.io/blog\/category\/berita\/#listItem","name":"Berita"}},{"@type":"ListItem","@id":"https:\/\/www.nanovest.io/blog\/category\/berita\/#listItem","position":2,"name":"Berita","item":"https:\/\/www.nanovest.io/blog\/category\/berita\/","nextItem":{"@type":"ListItem","@id":"https:\/\/www.nanovest.io/blog\/berita\/pfizer-optimis-hadapi-tantangan-kebijakan-dan-proyeksi-laba-2025-14773\/#listItem","name":"Pfizer Optimis Hadapi Tantangan Kebijakan dan Proyeksi Laba 2025"},"previousItem":{"@type":"ListItem","@id":"https:\/\/www.nanovest.io/blog#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/www.nanovest.io/blog\/berita\/pfizer-optimis-hadapi-tantangan-kebijakan-dan-proyeksi-laba-2025-14773\/#listItem","position":3,"name":"Pfizer Optimis Hadapi Tantangan Kebijakan dan Proyeksi Laba 2025","previousItem":{"@type":"ListItem","@id":"https:\/\/www.nanovest.io/blog\/category\/berita\/#listItem","name":"Berita"}}]},{"@type":"NewsArticle","@id":"https:\/\/www.nanovest.io/blog\/berita\/pfizer-optimis-hadapi-tantangan-kebijakan-dan-proyeksi-laba-2025-14773\/#newsarticle","name":"Pfizer Optimis Hadapi Tantangan Kebijakan dan Proyeksi Laba 2025 - Blog Nanovest","headline":"Pfizer Optimis Hadapi Tantangan Kebijakan dan Proyeksi Laba 2025","author":{"@id":"https:\/\/www.nanovest.io/blog\/author\/rian-jakawardana\/#author"},"publisher":{"@id":"https:\/\/www.nanovest.io/blog\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/www.nanovest.io/blog\/wp-content\/uploads\/2023\/03\/site-logo-color.png","@id":"https:\/\/www.nanovest.io/blog\/#articleImage","width":250,"height":250,"caption":"site-logo-color"},"datePublished":"2025-06-28T00:00:00+07:00","dateModified":"2025-06-28T00:00:00+07:00","inLanguage":"id-ID","mainEntityOfPage":{"@id":"https:\/\/www.nanovest.io/blog\/berita\/pfizer-optimis-hadapi-tantangan-kebijakan-dan-proyeksi-laba-2025-14773\/#webpage"},"isPartOf":{"@id":"https:\/\/www.nanovest.io/blog\/berita\/pfizer-optimis-hadapi-tantangan-kebijakan-dan-proyeksi-laba-2025-14773\/#webpage"},"articleSection":"Berita, Saham Global","dateline":"Published on Juni 28, 2025."},{"@type":"Organization","@id":"https:\/\/www.nanovest.io/blog\/#organization","name":"Nanovest","description":"Artikel dan Berita Kripto, Saham AS, dan Emas","url":"https:\/\/www.nanovest.io/blog\/","logo":{"@type":"ImageObject","url":"https:\/\/www.nanovest.io/blog\/wp-content\/uploads\/2023\/03\/site-logo-color.png","@id":"https:\/\/www.nanovest.io/blog\/berita\/pfizer-optimis-hadapi-tantangan-kebijakan-dan-proyeksi-laba-2025-14773\/#organizationLogo","width":250,"height":250,"caption":"site-logo-color"},"image":{"@id":"https:\/\/www.nanovest.io/blog\/berita\/pfizer-optimis-hadapi-tantangan-kebijakan-dan-proyeksi-laba-2025-14773\/#organizationLogo"},"sameAs":["https:\/\/www.facebook.com\/nanovest","https:\/\/twitter.com\/nanovest_io","https:\/\/www.instagram.com\/nanovest.io\/","https:\/\/www.youtube.com\/channel\/UC5Y5fD2FApTWMc0c2mlxzIg","https:\/\/www.linkedin.com\/company\/nano-vest\/"]},{"@type":"Person","@id":"https:\/\/www.nanovest.io/blog\/author\/rian-jakawardana\/#author","url":"https:\/\/www.nanovest.io/blog\/author\/rian-jakawardana\/","name":"Rian Jakawardana","image":{"@type":"ImageObject","@id":"https:\/\/www.nanovest.io/blog\/berita\/pfizer-optimis-hadapi-tantangan-kebijakan-dan-proyeksi-laba-2025-14773\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/629254e93aea20fec7b66121b57ce2b89b77c11bcde0df80552d7ea9f9c9defb?s=96&d=monsterid&r=g","width":96,"height":96,"caption":"Rian Jakawardana"}},{"@type":"WebPage","@id":"https:\/\/www.nanovest.io/blog\/berita\/pfizer-optimis-hadapi-tantangan-kebijakan-dan-proyeksi-laba-2025-14773\/#webpage","url":"https:\/\/www.nanovest.io/blog\/berita\/pfizer-optimis-hadapi-tantangan-kebijakan-dan-proyeksi-laba-2025-14773\/","name":"Pfizer Optimis Hadapi Tantangan Kebijakan dan Proyeksi Laba 2025 - Blog Nanovest","description":"Pfizer optimis pada kebijakan vaksin di era Trump meski kritik muncul, fokus pada reformasi biaya obat, proyeksi laba 2025 stabil, dan strategi inovasi baru.","inLanguage":"id-ID","isPartOf":{"@id":"https:\/\/www.nanovest.io/blog\/#website"},"breadcrumb":{"@id":"https:\/\/www.nanovest.io/blog\/berita\/pfizer-optimis-hadapi-tantangan-kebijakan-dan-proyeksi-laba-2025-14773\/#breadcrumblist"},"author":{"@id":"https:\/\/www.nanovest.io/blog\/author\/rian-jakawardana\/#author"},"creator":{"@id":"https:\/\/www.nanovest.io/blog\/author\/rian-jakawardana\/#author"},"datePublished":"2025-06-28T00:00:00+07:00","dateModified":"2025-06-28T00:00:00+07:00"},{"@type":"WebSite","@id":"https:\/\/www.nanovest.io/blog\/#website","url":"https:\/\/www.nanovest.io/blog\/","name":"Nanovest","alternateName":"Blog Nanovest","description":"Artikel dan Berita Kripto, Saham AS, dan Emas","inLanguage":"id-ID","publisher":{"@id":"https:\/\/www.nanovest.io/blog\/#organization"}}]},"og:locale":"id_ID","og:site_name":"Blog Nanovest - Artikel dan Berita Kripto, Saham AS, dan Emas","og:type":"article","og:title":"Pfizer Optimis Hadapi Tantangan Kebijakan dan Proyeksi Laba 2025 - Blog Nanovest","og:description":"Pfizer optimis pada kebijakan vaksin di era Trump meski kritik muncul, fokus pada reformasi biaya obat, proyeksi laba 2025 stabil, dan strategi inovasi baru.","og:url":"https:\/\/www.nanovest.io/blog\/berita\/pfizer-optimis-hadapi-tantangan-kebijakan-dan-proyeksi-laba-2025-14773\/","article:published_time":"2025-06-27T17:00:00+00:00","article:modified_time":"2025-06-27T17:00:00+00:00","article:publisher":"https:\/\/www.facebook.com\/nanovest","twitter:card":"summary_large_image","twitter:site":"@nanovest_io","twitter:title":"Pfizer Optimis Hadapi Tantangan Kebijakan dan Proyeksi Laba 2025 - Blog Nanovest","twitter:description":"Pfizer optimis pada kebijakan vaksin di era Trump meski kritik muncul, fokus pada reformasi biaya obat, proyeksi laba 2025 stabil, dan strategi inovasi baru.","twitter:creator":"@nanovest_io"},"aioseo_meta_data":{"post_id":"14773","title":null,"description":null,"keywords":null,"keyphrases":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":null,"og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":true,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":null,"robots_max_videopreview":null,"robots_max_imagepreview":"large","priority":null,"frequency":null,"local_seo":null,"seo_analyzer_scan_date":"2026-05-16 14:25:39","breadcrumb_settings":null,"limit_modified_date":false,"reviewed_by":null,"open_ai":null,"ai":null,"created":"2025-06-30 11:54:39","updated":"2026-05-16 14:25:39","focus_keyword":null,"additional_keywords":null,"truseo_locale":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t<a href=\"https:\/\/www.nanovest.io/blog\" title=\"Home\">Home<\/a>\n<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t<a href=\"https:\/\/www.nanovest.io/blog\/category\/berita\/\" title=\"Berita\">Berita<\/a>\n<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\tPfizer Optimis Hadapi Tantangan Kebijakan dan Proyeksi Laba 2025\n<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/www.nanovest.io/blog"},{"label":"Berita","link":"https:\/\/www.nanovest.io/blog\/category\/berita\/"},{"label":"Pfizer Optimis Hadapi Tantangan Kebijakan dan Proyeksi Laba 2025","link":"https:\/\/www.nanovest.io/blog\/berita\/pfizer-optimis-hadapi-tantangan-kebijakan-dan-proyeksi-laba-2025-14773\/"}],"_links":{"self":[{"href":"https:\/\/www.nanovest.io/blog\/wp-json\/wp\/v2\/posts\/14773","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nanovest.io/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nanovest.io/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nanovest.io/blog\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nanovest.io/blog\/wp-json\/wp\/v2\/comments?post=14773"}],"version-history":[{"count":0,"href":"https:\/\/www.nanovest.io/blog\/wp-json\/wp\/v2\/posts\/14773\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.nanovest.io/blog\/wp-json\/wp\/v2\/media?parent=14773"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nanovest.io/blog\/wp-json\/wp\/v2\/categories?post=14773"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nanovest.io/blog\/wp-json\/wp\/v2\/tags?post=14773"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}